Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits

BackgroundPatients with locally advanced prostate cancer (LAPCa) received docetaxel-based neoadjuvant chemo-hormonal therapy (NCHT) had better clinical outcomes after surgery compared to neoadjuvant hormonal therapy (NHT) groups, but not all patients experienced favorable clinical outcomes with NCHT...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Yinjie Zhu, Liancheng Fan, Hanjing Zhu, Yiming Gong, Chenfei Chi, Yanqing Wang, Jiahua Pan, Baijun Dong, Wei Xue
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Subjects:	predictive signature locally advanced prostate cancer transcriptomic profiling neoadjuvant chemo-hormonal therapy neoadjuvant hormonal therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.963411/full